Anthem BioSciences
- Market cap
- ₹ 45,767 Cr.
- P/E
- 79x
- P/B
- 14.78x
- 52-week range
- 579.15 – 977.55
- ROE
- 22%
- ROCE
- 30%
- Dividend yield
- 0.3%
- Debt / equity
- 0.02
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Biotechnology
- Listed on
- NSE, BSE
About
Anthem Biosciences Limited is an India-based contract research, development and manufacturing organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. The Company’s segments include CRDMO and Speciality Ingredients. The Company helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and others. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its CRDMO Services include Large Molecules, Small Molecules, HPAPI, Peptides, Lipids, ADCs and Oligonucleotides.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Biotechnology: 6 companies →Anthem BioSciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)79 against a typical 64.5: pricier than most peers (1st = cheapest).5th of 6
- Sales growth−22.6% against a typical +2.2% from a year earlier.4th of 5
- Profit growth−11.8% against a typical −50% from a year earlier.2nd of 5
- Share price, 3 months+5.4% against a typical −13.2%.2nd of 5
- Size₹ 45,766.9 Cr. market value against a typical ₹ 82.4 Cr. (1st = largest).1st of 6
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AA /[ICRA]A1+ | Stable | 2 Jul 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 2 Jul 2026 | ▲ Upgrade | [ICRA]AA /[ICRA]A1+ | — | ICRA | ₹ 275.5 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 21 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 19 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 5 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 8 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 13 Aug 2025 | Financial Results | Board Meeting intimation for consideration and approval of the Unaudited Consolidated and Standalone Financial Results for the quarter ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 |
| Expenses | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 |
| OPM % | 36% | 37% | 32% | 40% | 35% | 40% | 37% | 44% | 36% |
| Other Income | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 |
| Profit before tax | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 |
| Tax % | 30% | 19% | 23% | 54% | 27% | 24% | 29% | 32% | 17% |
| Net Profit | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 |
| EPS in Rs | 1.47 | 2.9 | 2.22 | 1.48 | 2.42 | 3.09 | 1.65 | 3.38 | 2.13 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 14%
- 3 Years
- 26%
- TTM
- −2%
- 10 Years
- —
- 5 Years
- 17%
- 3 Years
- 21%
- TTM
- 18%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 23%
- 3 Years
- 21%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Anthem BioSciences | ₹ 832.55 | ₹ 45,767 Cr. | 79x | 14.8x | 22% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Ajay Bhardwaj
- Chief Executive Officer, Managing Director (Promoter)
- Mohammed Gawir Gawir Baig
- Chief Financial Officer
- K Ravindra Chandrappa
- Whole Time Director, Chief Operating Officer
- Divya Prasad
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.